Four-part PumasCP End-to-End series demonstrates howclinical pharmacology teams can move from raw data to regulatory-readyreporting within a single reproducible environment
PumasAI, an AI-powered clinical pharmacology andpharmacometrics company transforming how pharmaceutical teams work, todayannounced the launch of PumasCP End-to-End, a new four-part educational webinarseries designed to help clinical pharmacology professionals streamlinepharmacokinetic (PK) analyses through a single reproducible environmentenhanced with artificial intelligence (AI).
The series will guide attendees throughevery stage of a modern clinical pharmacology workflow, beginning with rawconcentration data and ending with a submission-ready pharmacokinetic clinicalstudy report. Along the way, participants will see how AI can accelerate datapreparation, analysis, visualization, and reporting.
"As clinical pharmacology programs becomeincreasingly complex, organizations need workflows that are just assophisticated," said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI."Our goal with this series is to show how teams can eliminate unnecessaryhandoffs, improve reproducibility, and spend more time interpreting scienceinstead of managing disconnected software."
Designed for clinical pharmacologists, PK/PDscientists, pharmacometricians, quantitative scientists, regulatory professionals,and biostatisticians, the webinar series provides a practical look at howmodern technologies are reshaping clinical pharmacology analysis. Throughouteach session, attendees will also see how PumasAI's intelligent agents canaccelerate specific stages of the workflow while keeping scientists fully incontrol of every decision.
The four-part series includes:
● SessionA – Getting Started with PumasCP: Learn how to build analysis-readydatasets through data import, wrangling, CDISC-aligned ADNCA construction, andagent-assisted data preparation.
● Session B – From Concentrations to Conclusions: Explore noncompartmental analysis (NCA), bioequivalence, doseproportionality, and superposition analyses, alongside reusable workflows thatstandardize analyses across studies.
● Session C – Publication-Quality PK Graphics: Createhigh-quality pharmacokinetic figures using built-in templates and customvisualization tools designed for publication and regulatory submissions.
● Session D – Drafting the PK Clinical Study Report: Bring theentire workflow together by assembling tables, figures, listings, and reportnarratives into a reproducible, submission-ready pharmacokinetic report, with ademonstration of end-to-end agent capabilities inside PumasCP.
Each session combines live demonstrations with an"Agent Spotlight," illustrating how AI can assist scientiststhroughout the clinical pharmacology workflow, from preparing datasets throughdrafting regulatory documentation.
"Clinical pharmacology sits at thecenter of many critical development decisions," added Dr. Ivaturi."By bringing data preparation, analysis, visualization, and reportingtogether in one reproducible environment, we believe organizations can improveconsistency, accelerate timelines, and give scientists more time to focus onthe decisions that matter most."
The series also comes on the heels of the release of PumasCP 3.9, which expands the platform’svisualization capabilities with Advanced Figure support. Clinical pharmacologyteams can now create a wider range of customized, publication-quality andregulatory-ready plots directly within PumasCP, including concentration-over-timevisualizations, summary plots, box plots, violin plots, density plots, andhistograms. The release also supports company-standard themes and styling,giving teams greater control over how results are presented and helping carryreproducibility through analysis and reporting.
The PumasCP End-to-End webinar series begins September2, 2026, with additional sessions taking place on September 9, September 16,and September 23. Register to attend at https://pumas.ai/events/pumascp-end-to-end.
About PumasAI
PumasAI is an award-winning global healthcare intelligencecompany with a vision to accelerate precision healthcare to patients.Proprietary software and AI tools developed by the company includes the Pumassuite of products, an integrated modeling and simulation platform designed tomultiply productivity across the drug development lifecycle. Scientists atPumasAI provide consulting with leading pharmaceutical innovators in clinicalpharmacology, model-informed drug development (MIDD), pharmacometrics,front-end applications, and more.
For additional information, visit www.pumas.ai
Media Contact
Don F. McLean, McLean Media
+1-734-716-4182
###